Lexicon Pharmaceuticals (LXRX) Net Income towards Common Stockholders (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) reported Net Income towards Common Stockholders of -$996000.0 for Q1 2026, up 96.12% year-over-year from -$507848.9 in Q1 2025, and up 93.26% on a QoQ basis from -$14.8 million in Q4 2025.
Lexicon Pharmaceuticals (LXRX) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$996000.0 in Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 96.12% year-over-year to -$996000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$24.2 million (up 86.35% YoY) and the FY2025 annual result came in at -$48.9 million, up 75.19% from the prior year.
- Net Income towards Common Stockholders advanced to -$996000.0 in Q1 2026 per LXRX's latest filing, from -$14.8 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $3.7 million in Q2 2025 and bottomed at -$63.7 million in Q3 2024.
- The 5-year median for Net Income towards Common Stockholders is -$31.4 million (2022), against an average of -$31.2 million.
- The widest annual swing landed in 2023, when Net Income towards Common Stockholders plunged 123.42%; it then soared 106.75% in 2025.
- Tracing LXRX's Net Income towards Common Stockholders over 5 years: stood at -$31.4 million in 2022, then slumped by 48.93% to -$46.7 million in 2023, then increased by 29.95% to -$32.7 million in 2024, then surged by 54.85% to -$14.8 million in 2025, then surged by 93.26% to -$996000.0 in 2026.
- Per Business Quant, the three latest LXRX Net Income towards Common Stockholders figures stand at -$996000.0 (Q1 2026), -$14.8 million (Q4 2025), and -$12.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Lexicon Pharmaceuticals | 872.52 Mn | 701.87 Mn | 20.99 Mn | -996,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -996,000.00 |
| Dec 31, 2025 | -14.78 Mn |
| Sep 30, 2025 | -12.19 Mn |
| Jun 30, 2025 | 3.74 Mn |
| Mar 31, 2025 | -25.68 Mn |
| Dec 31, 2024 | -32.74 Mn |
| Sep 30, 2024 | -63.69 Mn |
| Jun 30, 2024 | -55.35 Mn |
| Mar 31, 2024 | -45.33 Mn |
| Dec 31, 2023 | -46.74 Mn |
| Sep 30, 2023 | -53.53 Mn |
| Jun 30, 2023 | -46.20 Mn |
| Mar 31, 2023 | -32.96 Mn |
| Dec 31, 2022 | -31.38 Mn |
| Sep 30, 2022 | -23.96 Mn |
| Jun 30, 2022 | -24.71 Mn |
| Mar 31, 2022 | -23.49 Mn |
| Dec 31, 2021 | -25.63 Mn |
| Sep 30, 2021 | -23.13 Mn |
| Jun 30, 2021 | -18.13 Mn |
| Mar 31, 2021 | -21.01 Mn |
| Dec 31, 2020 | -5.50 Mn |
| Sep 30, 2020 | 82.60 Mn |
| Jun 30, 2020 | -69.70 Mn |
| Mar 31, 2020 | -67.57 Mn |
| Dec 31, 2019 | -51.14 Mn |
| Sep 30, 2019 | 220.07 Mn |
| Jun 30, 2019 | -23.71 Mn |
| Mar 31, 2019 | -22.59 Mn |
| Dec 31, 2018 | -16.78 Mn |
| Sep 30, 2018 | -27.40 Mn |
| Jun 30, 2018 | -34.71 Mn |
| Mar 31, 2018 | -42.08 Mn |
| Dec 31, 2017 | -26.33 Mn |
| Sep 30, 2017 | -30.72 Mn |
| Jun 30, 2017 | -35.06 Mn |
| Mar 31, 2017 | -43.54 Mn |
| Dec 31, 2016 | -22.44 Mn |
| Sep 30, 2016 | -36.02 Mn |
| Jun 30, 2016 | -38.11 Mn |
| Mar 31, 2016 | -34.88 Mn |
| Dec 31, 2015 | 86.68 Mn |
| Sep 30, 2015 | -35.36 Mn |
| Jun 30, 2015 | -28.34 Mn |
| Mar 31, 2015 | -28.23 Mn |
| Dec 31, 2014 | -4.34 Mn |
| Sep 30, 2014 | -40.78 Mn |
| Jun 30, 2014 | -26.56 Mn |
| Mar 31, 2014 | -30.92 Mn |
| Dec 31, 2013 | -17.43 Mn |
| Sep 30, 2013 | -31.67 Mn |
| Jun 30, 2013 | -29.08 Mn |
| Mar 31, 2013 | -26.01 Mn |
| Dec 31, 2012 | -24.96 Mn |
| Sep 30, 2012 | -29.54 Mn |
| Jun 30, 2012 | -25.95 Mn |
| Mar 31, 2012 | -29.86 Mn |
| Dec 31, 2011 | -33.85 Mn |
| Sep 30, 2011 | -26.10 Mn |
| Jun 30, 2011 | -26.67 Mn |
| Mar 31, 2011 | -29.66 Mn |
| Dec 31, 2010 | -23.00 Mn |
| Sep 30, 2010 | -27.51 Mn |
| Jun 30, 2010 | -24.60 Mn |